Patent · US Active

Method of treating bacterial infections

US10828317B2 · kind B2 · utility

0Cited by

0References

24Claims

0Family size

Assignee

ULTUPHARMA AB · SE

Inventors

Bo F. Oberg · Uppsala, SE
Anders BROBERG · Uppsala, SE
Bengt Guss · Uppsala, SE
Jolanta Levenfors · Tierp, SE
Joakim Bjerketorp · Uppsala, SE
Christina NORD · Uppsala, SE

Key dates

Filing date	May 24, 2018
Grant date	Nov 10, 2020
Priority date	—
Expiry date	May 24, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.